Having -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To The Tricyclo Ring System Patents (Class 549/393)
  • Patent number: 9446021
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: September 20, 2016
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Wieslaw M. Cholody, Yi Zang, Karina Zuck, Jeffrey W. H. Watthey, Zoe Ohler, Jeffrey Strovel, Gene Ohler, Sheela Chellappan, Janak Padia
  • Patent number: 9120754
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: September 1, 2015
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Wieslaw M. Cholody, Yi Zang, Karina Zuck, Jeffrey W. H. Watthey, Zoe Ohler, Jeffrey Strovel, Gene Ohler, Sheela Chellappan, Janak Padia
  • Patent number: 8323750
    Abstract: The present invention relates to a UV irradiation assisted method of surface modification, which comprises: introducing a functional group L onto the surface of a polymer material P through the photochemical reaction of a photosensitive group X under UV irradiation, wherein the photosensitive group X comprises at least one xanthone unit.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: December 4, 2012
    Assignees: Beijing Wanhexinyuan BioTechnology Co., Ltd., Beijing University of Chemical Technology
    Inventors: Wantai Yang, Zhenhua Huang, Yanhe Tong, Lei Shao
  • Patent number: 7998541
    Abstract: The present invention relates to benzochromene derivatives of the formula I where the various parameters have the meaning indicated in the text, and to liquid-crystal media which comprise these compounds, and to the use of the media in electro-optical displays, in particular in TN, OCB, LCOS and/or IPS-LCDs, and to the use of the compounds and physiologically acceptable derivatives thereof as therapeutic active ingredients.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: August 16, 2011
    Assignee: Merck Patent GmbH
    Inventors: Andreas Taugerbeck, Elvira Montenegro, Atsutaka Manabe, Herbert Plach
  • Publication number: 20090182033
    Abstract: Compounds of formula (I) have muscarinic M3 receptor modulating activity; formula (I) wherein R1 is C1-C6-alkyl or a hydrogen atom; and R2 is a hydrogen atom or a group -R5 or a group, -Z-Y—R5, or a group -Z-NR9R10, or a group -Z-N(R9)C(O)R11; and R3 is a lone pair, or C1-C6-alkyl; R4 is selected from one of the groups of formula (a), (b), (c) or (d); formulae (a), (b), (c), (d), Z is a C1-C16-alkylene, C2-C16-alkenylene or C2-C16-alkynylene group; Y is a bond or oxygen atom; R5 is an C1-C6-alkyl, aryl, arylalkyl; aryl-fused-cycloalkyl, aryl-fused-heterocycloalkyl, heteroaryl, aryl(C1-C8-alkyl)-, heteroaryl(C1-C8-alkyl)-, cycloalkyl or heterocycloalkyl group; R6 is C1-C6-alkyl or a hydrogen atom; R7a and R7b area C1-C6-alkyl group or halogen; n and m are independently 0, 1, 2 or 3; R8a and R8b are independently selected from the group consisting of aryl, aryl-fused-heterocycloalkyl, heteroaryl, C1-C6-alkyl, cycloalkyl and hydrogen; R8c is —OH, C1-C6-alkyl, hydroxy-C1-C6-alkyl, or a hydrogen atom; R8d is C1-C6
    Type: Application
    Filed: December 14, 2006
    Publication date: July 16, 2009
    Applicant: ARGENTA DISCOVERY LTD.
    Inventors: Harry Finch, Nicholas Charles Ray, Monique Bodil Van Niel, Phillip Smith
  • Patent number: 7491832
    Abstract: The present invention provides a sulfonate compound including a structure represented by a general formula (I) below. In the formula (I), an atomic group A-O is an atomic group that forms a fluorescent compound upon cleavage of a covalent bond with a sulfonyl group. There may be one or plural atomic groups B—SO3— bound to an atomic group A. B is a ring substituted by one or plural electron-withdrawing groups. The electron-withdrawing group includes at least one selected from the group consisting of halogens, a carboxyl group, a carbamoyl group, a straight or branched alkylcarbamoyl group, a straight or branched alkanoyl group, a straight or branched alkoxycarbonyl group, a straight or branched alkyl halide group, and —NR3+ group (the three Rs each denote a hydrogen atom or a straight or branched alkyl group and may be the same or different). When there are plural Bs, the Bs may be the same or different.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: February 17, 2009
    Assignee: Osaka Industrial Promotion Organization
    Inventors: Hatsuo Maeda, Kazumasa Hirata, Kazuhisa Miyamoto
  • Patent number: 7465814
    Abstract: The present invention provides a sulfonate compound, including a structure represented by a general formula (I) below, where, in the formula (I), an atomic group A-O is an atomic group that forms a fluorescent compound upon cleavage of a covalent bond between the atomic group A-O and a sulfonyl group, one or a plurality of atomic groups B—SO3— are bonded to an atomic group A, B is a ring that is substituted by one or a plurality of electron-withdrawing groups, the electron-withdrawing group is at least one selected from the group consisting of an alkyl halide group, a nitro group and a cyano group, and B may be the same or different in kind in the case where the plurality of B exist.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: December 16, 2008
    Assignee: Osaka Industrial Promotion Organization
    Inventors: Hatsuo Maeda, Norio Itoh
  • Patent number: 7326447
    Abstract: The present invention relates to benzochromene derivatives of the formula I in which the various parameters are as defined in the text, and to liquid-crystal media which comprise these compounds, and to the use of the media in electro-optical displays, in particular in VAN LCDs.
    Type: Grant
    Filed: January 28, 2004
    Date of Patent: February 5, 2008
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Andreas Taugerbeck, Melanie Klasen-Memmer
  • Patent number: 7285672
    Abstract: The invention relates to a process for obtaining and purifying pure ?-mangostin from the rind of the fruit (mangosteen) of Garcinia mangostana.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: October 23, 2007
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rainer Sobotta, Hans-Peter Ignatow
  • Patent number: 7019024
    Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: March 28, 2006
    Assignee: Allelix Neuroscience Inc.
    Inventors: Vassil Iliya Ognyanov, Laurence A. Borden, Stanley Charles Bell, Jing Zhang
  • Patent number: 6740756
    Abstract: The present invention provides complexing agents of Formula I which contain novel photosensitizers and produce long-lived fluorescence for use in bioaffinity assays, especially HTRF (homogeneous time-resolved fluorescence) assays.
    Type: Grant
    Filed: June 20, 2001
    Date of Patent: May 25, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: George Wai-Kin Chan, Robert P. Hertzberg
  • Publication number: 20030073735
    Abstract: Disclosed are a novel compound represented by the following chemical formula (1), useful for the prophylaxis and treatment of angiogenic diseases, its production, and a novel microorganism producing the same. Aspergillus sp. Y80118 isolated from soil was found to produce 7,8-dihydro-1,7-dihydroxy-3-hydroxymethyl-xanthenone-8-carboxylic acid methylester which inhibits VEGF-induced proliferation of HUVEC, angiogensis in CAM assay, and tumor growth. The novel compound can be effectively used for the medical treatment of anigiogenic diseases, including cancers, rheumatoid arthritis, and diabetic retinopathy.
    Type: Application
    Filed: September 4, 2002
    Publication date: April 17, 2003
    Inventors: Jung Joon Lee, Hang Sub Kim, Young-Soo Hong, Yun Joo Park
  • Patent number: 6384045
    Abstract: This invention provides cancer-active tricyclic and tetracyclic oxypyrones and a method of synthesizing these compounds. Preferred compounds have aryl groups at the 3-position of the oxypyrone ring. The tricyclic oxypyrone synthetic method is a simple condensation reaction of pyrones with cyclohexenecarboxaldehydes, providing high yields and using few steps. The tetracyclic oxypyrone synthetic method is a simple condensation reaction of carvones with pyrones.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: May 7, 2002
    Assignee: Kansas State University Research Foundation
    Inventors: Duy H. Hua, Jean-Pierre Perchellet
  • Patent number: 6204396
    Abstract: A method produces calcium fulvate from naturally-occurring humus material, such as leonardite, or humic shales. The humus material containing solid fulvic acid and solid humic acid is mixed with water and sodium hydroxide for a first selected period of time to form a solution having a pH of approximately 10.0 thereby solubilizing the fulvic acid and the humic acid. The pH of the solution is reduced to approximately 4.5 and is maintained at the approximately pH 4.5 for second selected period of time thereby precipitating the humic acid as a solid while the fulvic acid remains in solution. The fulvic acid solution is separated from the solid humic acid. The pH of the fulvic acid solution is increased to approximately 13 with calcium hydroxide thereby precipitating the solubilized fulvic acid as calcium fulvate.
    Type: Grant
    Filed: December 29, 1999
    Date of Patent: March 20, 2001
    Assignee: Electrolytes, Inc.
    Inventors: Hans W. Rasmussen, Lawrence H. Allen
  • Patent number: 6147229
    Abstract: A method produces magnesium fulvate from naturally-occurring humus material, such as leonardite, or humic shales. The humus material containing solid fulvic acid and solid humic acid is mixed with water and sodium hydroxide for a first selected period of time to form a solution having a pH of approximately 10.0 thereby solubilizing the fulvic acid and the humic acid. The pH of the solution is reduced to approximately 4.5 and is maintained at the approximately pH 4.5 for second selected period of time thereby precipitating the humic acid as a solid while the fulvic acid remains in solution. The fulvic acid solution is separated from the solid humic acid. The pH of the fulvic acid solution is increased to approximately 13 with magnesium hydroxide thereby precipitating the solubilized fulvic acid as magnesium fulvate.
    Type: Grant
    Filed: December 27, 1999
    Date of Patent: November 14, 2000
    Assignee: Electrolytes, Inc.
    Inventors: Hans W. Rasmussen, Lawrence H. Allen
  • Patent number: 5977077
    Abstract: Therapeutic compositions for the treatment of infectious diseases are disclosed. These compositions comprise xanthones and xanthone derivatives, such as 2,3,4,5,6-pentahydroxyxanthone. Also disclosed are methods for the treatment of infectious diseases using such compounds.
    Type: Grant
    Filed: March 20, 1996
    Date of Patent: November 2, 1999
    Assignee: Interlab Corporation
    Inventors: Rolf Walter Winter, Michael Kevin Riscoe, David J. Hinrichs
  • Patent number: 5958970
    Abstract: This invention provides cancer-active tricyclic and tetracyclic oxypyrones and a method of synthesizing these compounds. Preferred compounds have aryl groups at the 3-position of the oxypyrone ring. The tricyclic oxyprone synthetic method is a simple condensation reaction of pyrones with cyclohexenecarboxaldehydes, providing high yields and using few steps. The tetracyclic oxypyrone synthetic method is a simple condensation reaction of carvones with pyrones.
    Type: Grant
    Filed: July 29, 1997
    Date of Patent: September 28, 1999
    Assignee: Kansas State University Research Foundation
    Inventors: Duy H. Hua, Jean-Pierre Perchellet
  • Patent number: 5763625
    Abstract: 3-Substituted-.beta.-lapachone analogs and their use either alone or to augment chemotherapy or radiotherapy to induce programmed neoplastic cell death without exhibiting toxicity to surrounding normal cells are disclosed. In particular, 3-allyl-.beta.-lapachones, 3-alkyl-.beta.-lapachones and 3-halo-.beta.-lapachones were found to be Topoisomerase (Topo I) inhibitors. When these analogs are used alone there is a reversible single-strand break in the DNA of neoplastic cells causing apoptosis and cell death in some cells. However, when these analogs are combined with chemotherapy or X-irradiation, an irreversible Topo I-mediated break is achieved. A new and more efficient chemical synthesis of the compounds is also disclosed.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: June 9, 1998
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: David A. Boothman, Benjamin J. Frydman, Donald T. Witiak
  • Patent number: 5726208
    Abstract: New compounds of formula: ##STR1## wherein: --A--D--E, X, n, Y and Z are as defined in the description, in racemic form and in the form of optical isomers,and their addition salts with pharmaceutically acceptable acids.Those compounds may be used as medicaments.
    Type: Grant
    Filed: October 11, 1996
    Date of Patent: March 10, 1998
    Assignee: Adir et Compagnie
    Inventors: Jean-Louis Peglion, Bertrand Goument, Jean-Christophe Harmange, Joel Vian, Aimee Dessinges, Mark Millan, Valerie Audinot
  • Patent number: 5672621
    Abstract: Carbonarins A, B, C, D, E, F, G, and H have been isolated from the sclerotia of the fungus Aspergillus carbonarius. The carbonarius are effective for controlling Coleopteran and Lepidopteran insects. The carbonarins have the structure: ##STR1## wherein: R.sub.1 is a hydrogen atom or a hydroxy group; R.sub.2 is a hydrogen atom or a methoxy group; R.sub.3 is a hydrogen atom or a naphthopyrone group; and X is an oxygen atom or an NH group.
    Type: Grant
    Filed: February 27, 1996
    Date of Patent: September 30, 1997
    Assignees: The United States of America as represented by the Secretary of Agriculture, University of Iowa Research Foundation and Biotechnology Research and Development Corp.
    Inventors: Ali A. Alfatafta, Patrick F. Dowd, James B. Gloer, Donald T. Wicklow
  • Patent number: 5633357
    Abstract: A method of producing a carboxylic acid glucuronide by reacting a carboxylic acid precursor with a blocked sugar epoxide precursor is disclosed. Also disclosed are: deuterated 11-nor-.DELTA..sup.8 - or .DELTA..sup.9 -THC carboxylic acid glucuronide having a deuterated hydrocarbon chain; 5'-deuterated 11-nor-.DELTA..sup.8 - or .DELTA..sup.9 -THC-carboxylic acid or 5'-deuterated .DELTA..sup.8 - or .DELTA..sup.9 -THC glucuronide. The compositions are useful as GC-MS standards; in methods for preparing antibodies reactive with a THC glucuronide; and, in GC-MS diagnostic methods for THC metabolites.
    Type: Grant
    Filed: March 4, 1994
    Date of Patent: May 27, 1997
    Assignee: Synthetic Technology Corporation
    Inventors: Marcus A. Tius, Mark R. Hagadone
  • Patent number: 5623080
    Abstract: A compound of the formula (I) or (II): ##STR1## where R.sup.1, R.sup.2, R.sup.5 and R.sup.6 are the same or different and represent a hydrogen atom or a halogen atom and R.sup.1 and R.sup.2 may combine to form a ring; R.sup.3, and R.sup.4 are the same or different and represent a hydrogen atom, a halogen atom, a benzoyl group, a group of the formula --L(CH.sub.2).sub.n R.sup.8 where n is 1 to 8, R.sup.8 is a hydrogen, hydroxy, amino, dialkylamino, --COR.sup.16 or --COOR.sup.14 where R.sup.16 is a hydrogen, chlorine, COCl, C.sub.1 -C.sub.8 alkyl, --NR.sub.2 or aryl and R.sup.14 is a hydrogen, C.sub.1 -C.sub.8 alkyl, aryl, COR, 2,4-dinitrophenyl, N-imido or --NR.sub.2 and L is a direct bond or C.dbd.O; W is .dbd.O; W.sup.1 is hydrogen or --OR.sup.9, where R.sup.9 is hydrogen, C.sub.1 -C.sub.8 alkyl, acyl or a group of the formula --(CH.sub.2).sub.n R.sup.10 where n is 1 to 8 and R.sup.10 is amino, dialkylamino, hydroxy, acryloyl or methacryloyl; Y is oxygen, sulfur, selenium, tellurium, C.dbd.O, or >N--R.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: April 22, 1997
    Assignee: Spectra Group Limited, Inc.
    Inventors: Douglas C. Neckers, Jianmin Shi
  • Patent number: 5597943
    Abstract: The present invention relates to the new thielocin derivatives, which exhibit phospholipase A.sub.2 inhibitory activity of the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are independently hydrogen, lower alkyl, lower alkoxy, hydroxy, or halogen;E.sub.1 and E.sub.2 are independently hydrogen, or an ester residue;m and n are independently an integer of 0 to 4;--Y-- is a bivalent group which is selected from the group consisiting of the following radicals: ##STR2## or the salts thereof.
    Type: Grant
    Filed: December 13, 1995
    Date of Patent: January 28, 1997
    Assignee: Shionogi & Co., Ltd.
    Inventors: Mitsuaki Ohtani, Shigeru Matsutani, Tadashi Yoshida, Kazushige Tanaka, Yasuhiko Fujii, Kazuhiro Shirahase
  • Patent number: 5563278
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: October 8, 1996
    Assignee: Eli Lilly and Company
    Inventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
  • Patent number: 5011952
    Abstract: A compound of the formula: ##STR1## wherein the wave line means .alpha.-bond or .beta.-bond, which compound is useful as a phospholipase A.sub.2 inhibitor. Process for the production of the compound, pharmaceutical composition containing the compound, and a cell culture of a microorganism Thielavia terricola RF-143 producing the compound are also provided.
    Type: Grant
    Filed: April 30, 1990
    Date of Patent: April 30, 1991
    Assignee: Shionogi & Co., Ltd.
    Inventors: Tadashi Yoshida, Keizo Inoue, Hitoshi Arita, Shigeru Matsutani, Jun'ichi Shoji, Yoshimi Kawamura
  • Patent number: 4996230
    Abstract: This invention provides tricyclic derivatives which are leukotriene B.sub.4 antagonists, formulations of those derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.
    Type: Grant
    Filed: February 16, 1990
    Date of Patent: February 26, 1991
    Assignee: Eli Lilly and Company
    Inventor: D. Mark Gapinski
  • Patent number: 4927849
    Abstract: The xanthosulfonamido and benzensulfonamido derivatives corresponding to the formula: ##STR1## wherein x represents hydrogen, alkyl, alkoxy or halogen, Y represents an alkyl, alkoxy or halogen and Z represents the group ##STR2## or Y and Z taken together form the group: ##STR3## wherein R.sub.1 in turn is a group selected among electron attracting groups, halogens and the group: ##STR4## itself, possess activity in inhibiting the aldose-reductase enzyme system and are thus useful in the treatment of the complications, at the eye and peripheral neuropathy levels, as induced by diabetes.
    Type: Grant
    Filed: September 16, 1988
    Date of Patent: May 22, 1990
    Assignee: Laboratori Baldacci SpA
    Inventors: Giulio Caccia, Massimo Baldacci
  • Patent number: 4691059
    Abstract: This invention describes UV-stabilized step growth polymers such as polyesters, polyurethanes, polycarbonates, and combinations thereof. The UV-stabilizing moieties present in these polymers comprise chemically bound, pendant ortho-hydroxydiphenyl ketone based moieties. The polymers are especially useful as protective films and fibers which are highly resistant to ultraviolet (UV) and sunlight degradation.
    Type: Grant
    Filed: August 30, 1985
    Date of Patent: September 1, 1987
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: Sumita B. Mitra, Smarajit Mitra
  • Patent number: 4628087
    Abstract: Process for the preparation of pharmacologically active compounds containing a sulfoxide group by oxidation of a thioether with hypochlorite in an alkaline medium at a pH higher than 10 and at a temperature comprised between 0.degree. and 40.degree. C.
    Type: Grant
    Filed: May 7, 1984
    Date of Patent: December 9, 1986
    Assignee: Zambon S.p.A.
    Inventor: Mariano Meneghin
  • Patent number: 4585876
    Abstract: Novel xanthones and thioxanthones of the formula I ##STR1## in which A, X, Y, Z, E and E' are as defined in patent claim 1, are described. A is preferably --S-- and E and E' are preferably bonded in the ortho-position relative to one another. The compounds (I) are suitable, for example, as sensitizers for photocrosslinkable polymers or photocurable compositions, or for use in mixtures with polymers with H donor groups for image formation, in particular electrically conductive coatings and patterns, by means of electroless deposition of metals.
    Type: Grant
    Filed: November 14, 1983
    Date of Patent: April 29, 1986
    Assignee: Ciba-Geigy Corporation
    Inventors: Walter Fischer, Jurgen Finter, Hans Zweifel
  • Patent number: 4556651
    Abstract: A secalonic acid derivative of the formula (I); ##STR1## wherein R is ##STR2## wherein R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-4 alkyl group; R.sub.3 is a hydrogen atom, a C.sub.1-4 alkyl group, and aryl group, a C.sub.1-5 alkoxy group, a halogen atom, a cyano group, a carboxyl group, a sulfonic acid group, a carboxylic acid amide group or a sulfonic acid amide group; and R.sub.4 is a saturated or unsaturated C.sub.1-22 alkyl group, an aryl group or an aryl alkyl group, and may have a substituent; and the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 6, 1983
    Date of Patent: December 3, 1985
    Assignee: Asahi Kasei Kogyo Kabushiki Kaisha
    Inventors: Mitsuru Shibukawa, Chisei Shibuya, Kunihiko Ishii
  • Patent number: 4496447
    Abstract: Compounds of the formula ##STR1## wherein A, X, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, n and m are defined hereinbelow are effective photoinitiators especially for the photopolymerization of ethylenically unsaturated compounds and for the curing of printing inks.
    Type: Grant
    Filed: December 21, 1982
    Date of Patent: January 29, 1985
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Jurgen Eichler, Claus Herz, Karl-Heinz Neisius, Gregor Wehner
  • Patent number: 4424373
    Abstract: Secalonic acids having a 2,4'-linkage of the formula (I) or a 4,4'-linkage of the formula (II). ##STR1## .
    Type: Grant
    Filed: August 11, 1982
    Date of Patent: January 3, 1984
    Assignee: Asahi Kasei Kogyo Kabushiki Kaisha
    Inventors: Itsuo Kurobane, Leo C. Vining, Alister G. McInnes